use of the p2x7 antagonist o atp or bbg treatment of the neurodegerative phases of multiple multiple sclerosis

摘要

The present invention is related to the treatment of demyelinating and autoimmune diseases, more particularly with the treatment of multiple sclerosis. The treatment consists of the administration of P2X purinergic receptors antagonist substances which cause a remission of the symptoms common to these types of diseases. This is demonstrated in in vitro cell models as well as in animal models.